Enfusion

Enfusion, Inc. engages in the development of cloud-native multi-tenant software for alternative and institutional investment managers. It is a software-as-a-service firm that develops a platform to eliminate technology and information barriers, and simplify investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset. The company was founded by Tarek Hammoud, Stephen M. Malherbe, Oleg Movchan, and Scott Werner in 2006 and is headquartered in Chicago, IL.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Enfusion reports robust Q4 earnings, eyes growth in new markets

Enfusion's Q4 2022 performance reflects financial strength and growth momentum, supported by revenue growth, client wins, and strategic guidance for 2023.
The company's strengths lie in its market positioning, regional focus, and commitment to innovation, while challenges include managing churn levels and scaling managed services profitably.
Opportunities in expanding into new markets, enhancing client relationships, and driving revenue growth through strategic initiatives position Enfusion for continued success and market leadership.
Overall, Enfusion's proactive approach to market dynamics, client services, and product development sets a solid foundation for sustained growth and value creation, aligning with investor expectations and industry trends.

Enfusion reports robust Q1 earnings, eyes growth amid market challenges

Enfusion's Q1 2023 Earnings Call highlighted strong financial performance, strategic partnerships, and a positive outlook for the year. Despite market challenges, the company remains resilient and focused on growth opportunities. Management's reaffirmation of guidance and optimism for the future reflect confidence in Enfusion's trajectory.

Enfusion reports strong Q2 earnings, eyes growth through strategic partnerships

Enfusion's Q2 performance showcased growth and profitability despite challenges. The company's strategic focus on efficiency, partnerships, and tailored pricing strategies bodes well for future expansion and revenue generation.

Enfusion reports robust Q3 performance and eyes sustainable 20% growth

Enfusion's Q3 performance showcased strong revenue growth, client additions, and global market expansion, with a focus on Portfolio WorkBench.
Confidence in reaffirmed guidance, positive organic growth trends, and strategic investments position Enfusion for sustained success.
Challenges include managing quarterly fluctuations, balancing investments for growth, and addressing strategic clarity in key areas.
Opportunities lie in leveraging product capabilities, targeted investments, ACV growth, and global market expansion for continued success.

Enfusion reports robust Q4 earnings, eyes growth through technology innovation

Enfusion's strong Q4 performance, focus on SaaS platform benefits, and strategic guidance for 2024 demonstrate a commitment to growth and innovation. The company's emphasis on client service, technology enhancements, and market opportunities positions them well for future success. Enfusion's Investor Day in Fort Lauderdale on March 19 will showcase their integrated investment technology platform and growth outlook.

Enfusion excels in Q1 performance, eyes growth through client focus

Enfusion's Q1 2024 performance showcased strong revenue growth, client wins, and margin expansion, driven by efficient client onboarding and product enhancements.
The company's strengths in client relationships, differentiated offerings, and strategic pricing position it well for future growth and value creation.
Challenges in client fee pressure, resource allocation, and evolving seasonality require strategic solutions, while opportunities in product enhancements and growth algorithm offer avenues for expansion.
Enfusion's commitment to delivering on promises, shareholder value creation, and differentiation underpin its optimistic outlook and focus on long-term success.

Enfusion reports robust Q2 earnings, eyes global expansion opportunities

Enfusion's Q2 performance reflects strong revenue growth, client acquisitions, and product innovation.
The company's resilience to market forces and global expansion efforts position it for continued success.
Challenges lie in maintaining growth momentum, deepening client relationships, and adapting to market dynamics.

Enfusion reports robust Q3 growth, eyes sustained expansion and innovation

Enfusion's Q3 2024 earnings call highlighted strong financial performance, client acquisitions, and product advancements. The company's tightened revenue and EBITDA guidance for 2024 reflects management's confidence in continued growth. Analyst inquiries centered on strategic alternatives, product innovations, and revenue drivers, indicating investor interest in Enfusion's future prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Enfusion Inc Investors Encouraged To Join Securities Fraud Investigation Led By The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.

Enfusion, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Enfusion (ENFN)

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.

ENFN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Stockholders to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Who Lost Money In Enfusion Inc Invited To Join Securities Fraud Investigation Led By The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.

ENFN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Shareholders to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Enfusion Inc Shareholders Invited To Participate In Securities Fraud Investigation Led By The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.

Levi & Korsinsky Reminds Shareholders of an Investigation into Enfusion, Inc. (ENFN) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.

ENFN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Shareholders to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Invited To Join The Securities Fraud Investigation Of Enfusion, Inc. By The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.

ATTENTION ENFN SHAREHOLDERS: Investors who lost money on Enfusion, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.

ENFN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Shareholders to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Enfusion Inc Investors Urged To Participate In Securities Fraud Investigation Led By The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.

ENFN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.

Enfusion, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ENFN

Shareholder Rights Advocates at Levi & Korsinsky Investigate Enfusion, Inc. (ENFN) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.

ENFN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Investors to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.

Lost Money on Enfusion, Inc. (ENFN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.

ENFN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Investors to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Invited to Participate in Securities Fraud Investigation Against Enfusion, Inc. with the Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE: ENFN ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Invited to Participate in Enfusion, Inc. Securities Fraud Investigation by the Schall Law Firm

ENFN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on your Enfusion, Inc. Investment

Enfusion, Inc. (NYSE:ENFN ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Bill Wright - Head, IR Oleg Movchan - CEO Bradley Herring - CFO Neal Pawar - COO Conference Call Participants Michael Infante - Morgan Stanley Faith Brunner - William Blair Gabriela Borges - Goldman Sachs Alexei Gogolev - JPMorgan Matthew Kikkert - Stifel Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

Enfusion, Inc. (ENFN) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Enfusion (ENFN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Enfusion (ENFN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.04 per share a year ago.

Enfusion, Inc. (ENFN) Q2 Earnings and Revenues Miss Estimates

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its second quarter 2024 financial results as part of its Q2 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 2Q24 Earnings Conference Call Management will host a conference call today, August 6, 2024, at 8:30 AM ET t.

News for Enfusion Stock (ENFN)